Normal AMH for a 49-Year-Old Woman
For a 49-year-old woman, AMH levels are expected to be very low, typically in the range of 0.14-5.10 pmol/L (approximately 0.02-0.71 ng/mL), with a median around 0.68 pmol/L (approximately 0.09 ng/mL).
Age-Specific Reference Ranges
At age 49, women are approaching or entering menopause, and AMH levels reflect the natural decline in ovarian reserve that accelerates significantly after age 40. The evidence consistently demonstrates this pattern:
- Ages 46-50 years: The reference range (2.5th to 97.5th percentiles) is 0.14-5.10 pmol/L, with a median of 0.68 pmol/L 1
- Ages 40-55 years: The reference range is 0.08-5.70 ng/mL, with a median of 1.09 ng/mL 2
- Ages >43 years: Median AMH is 0.67 ng/mL 3
Clinical Context and Interpretation
AMH declines progressively with age, following an exponential pattern. In healthy women aged ≥25 years, AMH is inversely correlated with increasing age 4. The decline becomes particularly pronounced after age 36-40 5, 2.
Key Points for Clinical Use:
Wide individual variation exists: Even within the same age group, there is substantial variability in AMH levels among healthy women 4
Postmenopausal distinction: AMH can help distinguish postmenopausal from premenopausal women, with postmenopausal women having significantly lower levels (median 0.043 ng/mL vs. 0.187 ng/mL in premenopausal women) 6
Ovarian reserve marker: AMH reflects follicle stock as it is secreted by follicle granulosa cells and slows follicle loss by partly inhibiting FSH action 7
Important Caveats
Assay sensitivity matters: At age 49, AMH levels are often at the lower detection limits of conventional assays. Ultrasensitive assays (with detection limits as low as 0.003 ng/mL) are preferable for accurate measurement in this age group 6.
Clinical correlation required: While low AMH at this age is physiologically normal and reflects natural ovarian aging, interpretation should always be combined with:
- Menstrual history (regularity, cycle length)
- FSH and estradiol levels if evaluating for premature ovarian insufficiency
- Clinical symptoms (vasomotor symptoms, menstrual irregularities)
Not diagnostic alone: AMH should not be used as a standalone marker but rather as part of comprehensive assessment of ovarian function 7, 4.